The efficacy of all available GnRH antagonists has been tested through RCTs and approved by the necessary regulatory bodies (e.g., EMA, FDA). At 24 weeks, all GnRH antagonists have been shown to have more than 70% efficacy, increasing up to 90% at week 52 (defined as menstrual blood loss ≤80ml and ≥ 50% reduction from baseline over last 28 days before Week 24)
As with all treatments and clinical trials ,there may be important differences between them, in terms of methodology, population and placebo response rate. Potential differences are:
- Patient demographics with respective to the pivotal trials
- Level of efficacy achieved in clinical trials and from each different dosing option
- Placebo response rates
These differences may impact the reproducibility of clinical trial results in real clinical practice and patients. 1,2 It is important, therefore, to consult any treatment’s licensed SmPC and consider before treatment1,2
